Safety and efficacy of COVID-19 Vaccines in special populations
DOI:
https://doi.org/10.22317/jcms.v8i2.1197Keywords:
COVID-19, SARS-CoV-2, Johnson & Johnson’s, Pfizer, Moderna, vaccineAbstract
Coronavirus disease 2019 (COVID-19), is a pandemic that resulted in extreme human and economic losses. A higher incidence of morbidity and mortality to COVID-19 was demonstrated in a special population. Factors that impact the disease severity include old age, obesity, pregnancy, diabetes mellitus, cancer, and immunosuppressive drugs. Fortunately, several COVID-19 vaccines were developed such as Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, and Johnson & Johnson among others. These vaccines have shown good efficacy and safety profiles in the general population, but serious rare adverse effects were reported related to specific vaccines. Several studies are undergoing to test the efficacy in special populations. Reduced efficacy or delayed immunological response to COVID-19 vaccines were suggested for patients with autoimmune disorders or organ transplant patients, especially those receiving certain medications such as rituximab. There is a concern about organ rejection in organ transplant patients. Despite these facts, there is an agreement among health care providers to consider prioritization of the above-mentioned groups for receiving vaccinations with the same precautions followed for the general population. It is recommended to ongoing studies determine the efficacy and safety of COVID-19 vaccines in patients with comorbidities based on clinical data.
References
Roser, M., et al., Coronavirus pandemic (COVID-19), in Our world in data. 2021, Our world in data.
Belete, T.M., Review on up-to-date status of candidate vaccines for COVID-19 disease. Infection and drug resistance, 2021. 14: p. 151.
Yong, C.Y., et al., Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Frontiers in microbiology, 2019. 10: p. 1781.
Krammer, F., SARS-CoV-2 vaccines in development. Nature, 2020. 586(7830): p. 516-527.
Goodman, J.L., J.D. Grabenstein, and M.M. Braun, Answering key questions about COVID-19 vaccines. Jama, 2020. 324(20): p. 2027-2028.
Francis, A.I., et al., Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgraduate Medical Journal, 2021.
Perry, C., et al., Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Advances, 2021. 5(16): p. 3053-3061.
McDonald, I., et al., Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARSCoV-2. npj Vaccines, 2021. 6(1): p. 1-14.
Lv, M., et al., Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines, 2021. 9(10): p. 1102.
Frenck Jr, R.W., et al., Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine, 2021.
Das, B.B., et al., Myopericarditis after messenger RNA coronavirus disease 2019 vaccination in adolescents 12 to 18 years of age. The Journal of Pediatrics, 2021. 238: p. 26-32. e1.
Schauer, J., et al., Myopericarditis after the Pfizer messenger ribonucleic acid coronavirus disease vaccine in adolescents. The Journal of pediatrics, 2021. 238: p. 317-320.
Mahase, E., Covid-19: Pfizer and BioNTech submit vaccine for US authorisation. 2020, British Medical Journal Publishing Group.
Walsh, E.E., et al., Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine, 2020. 383(25): p. 2439-2450.
Polack, F.P., et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2020.
Boyarsky, B.J., et al., Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. Jama, 2021. 325(17): p. 1784-1786.
Gray, K.J., et al., Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. American Journal of Obstetrics and Gynecology, 2021.
Dagan, N., et al., Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature medicine, 2021. 27(10): p. 1693-1695.
Teo, S.P., Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. Journal of Pharmacy Practice, 2021: p. 08971900211009650.
Heaton, P.M., The Covid-19 vaccine-development multiverse. 2020, Mass Medical Soc. p. 1986-1988.
Kaur, S.P. and V. Gupta, COVID-19 Vaccine: A comprehensive status report. Virus research, 2020: p. 198114.
Baden, L.R., et al., Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 2021. 384(5): p. 403-416.
Bruxvoort, K.J., et al., Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. bmj, 2021. 375.
Oosting, S.F., et al., mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. The Lancet Oncology, 2021. 22(12): p. 1681-1691.
John, B.V., et al., Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA internal medicine, 2021. 181(10): p. 1306-1314.
Lacson, E., et al., Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. medRxiv, 2021.
Shimabukuro, T.T., et al., Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine, 2021. 384(24): p. 2273-2282.
Mahase, E., How the Oxford-AstraZeneca covid-19 vaccine was made. bmj, 2021. 372.
Folegatti, P.M., et al., Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial. The Lancet, 2020. 396(10249):p. 467-478.
Hung, I.F. and G.A. Poland, Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster. The Lancet, 2021. 397(10277): p. 854-855.
Sheikh, A., et al., SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet, 2021.
Voysey, M., et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2021. 397(10269): p. 99-111.
Iheanacho, C.O., U.I. Eze, and E.A. Adida, A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population. Bulletin of the National Research Centre, 2021. 45(1): p. 1-10.
Hernández, A.F., et al., Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicology Reports, 2021. 8: p. 871-879.
Ramasamy, M.N., et al., Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 2020. 396(10267): p. 1979-1993.
See, I., et al., US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. Jama, 2021.
Bhuyan, P., et al., Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis. The Lancet, 2021. 398(10300): p. 577-578.
Sharifian-Dorche, M., et al., Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Journal of the neurological sciences, 2021. 428: p. 117607.
Shan, Y., et al., Multisystem inflammatory syndrome in an adult after COVID-19. Infectious Diseases in Clinical Practice, 2020. 28(6): p. e28-e29.
Marammatom, B.V., et al., Guillain‐Barré syndrome following ChAdOx1‐S/nCoV‐19 vaccine. Annals of Neurology, 2021.
Maurya, M.R., R. Ravi, and L. Pushparajan, Serious adverse events following immunization after ChAdOx1 nCov-19 vaccination in India: a single center experience. The Pan African Medical Journal, 2021. 40.
MacIntyre, C.R., et al., Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination–A risk–benefit analysis for people< 60 years in Australia. Vaccine, 2021. 39(34): p. 4784-4787.
Frater, J., et al., Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. The Lancet HIV, 2021.
Asano, M., et al., Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases, 2022. 114: p. 165-174.
Masset, C., et al., Pancreas allograft rejection occurring after ChAdOx1 nCoV-19 vaccine. Diabetes & Metabolism, 2021.
Edwards, A.E., et al., Acute hyperglycaemic crisis after vaccination against COVID‐19: A case series. Diabetic Medicine, 2021.
Abbink, P., et al., Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology, 2007. 81(9): p. 4654-4663.
Oliver, S.E., et al., The advisory committee on immunization practices’ interim recommendation for use of Janssen COVID-19 vaccine—United States, February 2021. Morbidity and Mortality Weekly Report, 2021. 70(9):p. 329.
Bos, R., et al., Ad26 vector-based COVID-19 vaccine encoding a prefusionstabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. npj Vaccines, 2020. 5(1): p. 1-11.
Sadoff, J., et al., Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021. 384(19): p. 1824-1835.
Bos, R., et al., Ad26 vector-based COVID-19 vaccine encoding a prefusionstabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020 Sep 28; 5: 91. doi: 10.1038/s41541-020-00243-x. PMID: 33083026; PMCID: PMC7522255.
Sadoff, J., et al., Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine, 2021. 384(23): p. 2187-2201.
Alter, G., et al., Immunogenicity of Ad26. COV2. S vaccine against SARSCoV-2 variants in humans. Nature, 2021. 596(7871): p. 268-272.
Thiagarajan, K., What do we know about India’s Covaxin vaccine? BMJ:British Medical Journal (Online), 2021. 373.
Robert Carlson and H. Lutmer. Covaxin COVID-19 Vaccine. 2021 [cited 2021 13 december]; Available from: https://www.precisionvaccinations.com/vaccines/covaxin-covid-19-vaccine.
Ella, R., et al., Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. The Lancet, 2021.
COVID-19 vaccines, in Drugs and Lactation Database (LactMed). 2006, National Library of Medicine (US): Bethesda (MD).
Gao, Q., et al., Development of an inactivated vaccine candidate for SARSCoV-2. Science, 2020. 369(6499): p. 77-81.
Rego, G.N., et al., Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines, 2020. 8(3): p. 474.
Asyura, M.M.A.Z., et al., Immunogenicity and Safety Analysis of Inactivated Virus Vaccine against SARS-CoV-2: A Systematic Review of Phase 1/2 Clinical Trials. Journal of Asian Medical Students’ Association, 2021. 9(1).
Lapitan, M.C., J.C. Valencia, and M.A. Castor, Is CoronaVac (Sinovac) effective and safe in the prevention of COVID-19-infections?: A Rapid Review (Update).
Palacios, R., et al., Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. 2021.
Tanriover, M.D., et al., Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 2021. 398(10296): p. 213-222.
Benjamanukul, S., et al., Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. J Med Virol, 2021.
Bueno, S.M., et al., Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis, 2021.
Fernandes, E.G., et al., Safety and immunogenicity of an inactivated SARSCoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children. Rev Inst Med Trop Sao Paulo, 2021. 63: p. e83.
Han, B., et al., Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021. 21(12): p. 1645-1653.
Medeiros-Ribeiro, A.C., et al., Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med, 2021. 27(10): p. 1744-1751.
Tosun, S., et al., Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers. Postgrad Med, 2021: p. 1-7.
Uzer, F. and A. Cilli, Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report. Med Gas Res, 2022. 12(2): p. 67-68.
Wan, E.Y.F., et al., Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis, 2021.
Wu, Z., et al., Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021. 21(6): p. 803-812.
Zhao, H., Y. Li, and Z. Wang, Adverse event of Sinovac Coronavirus vaccine: Deafness. Vaccine, 2021.
Alencar, C.H., et al., High effectiveness of SARS-CoV-2 vaccines in reducing COVID-19-related deaths in over 75-year-olds, Ceara state, Brazil. Tropical Medicine and Infectious Disease, 2021. 6(3): p. 129.
Karacin, C., et al., Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncology, 2021. 17(33): p. 4447-4456.
Medeiros-Ribeiro, A.C., et al., Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature medicine, 2021. 27(10): p. 1744-1751.
Seyahi, E., et al., Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatology international, 2021: p. 1-12.
Robert Carlson and H. Lutmer. Sinopharm COVID-19 Vaccine (BBIBPCorV). 2021 [cited 2021 15 december]; Available from: https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv.
Wang, H., et al., Development of an inactivated vaccine candidate, BBIBPCorV, with potent protection against SARS-CoV-2. Cell, 2020. 182(3): p. 713-721. e9.
Al Kaabi, N., et al., Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. Jama, 2021.
WHO. Evidence Assessment:Sinopharm/BBIBP COVID-19 vaccine. 2021 [cited 2021 15 december]; Available from: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_criticalevidence_sinopharm.pdf.
Ariamanesh, M., et al., Immunogenicity and Safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Investigation, 2021: p. 1-9.
Burki, T.K., The Russian vaccine for COVID-19. The Lancet Respiratory Medicine, 2020. 8(11): p. e85-e86.
Logunov, D.Y., et al., Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 2021. 397(10275): p. 671-681.
Rossi, A.H., et al., Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine, 2021. 2(8): p. 100359.
Baraniuk, C., Covid-19: What do we know about Sputnik V and other Russian vaccines? bmj, 2021. 372.
Bucci, E.M., et al., Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet, 2021. 397(10288): p. 1881-1883.
Babamahmoodi, F., et al., Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Scientific Reports, 2021. 11(1): p. 1-8.
Mehraeen, E., S. SeyedAlinaghi, and A. Karimi, Can children of the Sputnik V vaccine recipients become symptomatic? Human Vaccines & Immunotherapeutics, 2021. 17(10): p. 3500-3501.
González, S., et al., Effectiveness of the first component of Gam-COVIDVac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine, 2021. 40: p. 101126.
Tsimafeyeu, I., et al., Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. Journal of hematology & oncology, 2021. 14(1): p. 1-7.
Biospace. UPDATED Comparing COVID-19. 2021 [cited 2021 15 December]; Available from: https://www.biospace.com/article/ comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazenecaoxford-j-and-j-russia-s-sputnik-v/.
Gov.Canda. COVID-19 vaccines and treatments portal. 2022 [cited 2022 10 Februray]; Available from: COVID-19 vaccines and treatments portal.
CDC. Selected Adverse Events Reported after COVID-19 Vaccination. 2021 Updated June 23, 2021 [cited 2021 26 JUNE]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.
Spiera, R., S. Jinich, and D. Jannat-Khah, Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2021.
Simon, D., et al., SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases. Annals of the rheumatic diseases, 2021.
Soy, M., et al., A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clinical Rheumatology, 2021: p. 1-13.
Peter, J., COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases. South African Medical Journal, 2021. 111(4): p. 291-294.
Erskine, D. Using COVID-19 vaccines in patients with anticoagulation and bleeding disorders. 2021 [cited 2021 10 June ]; Available from: https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-patients-withanticoagulation-and-bleeding-disorders/.
Velikov, T., G. Keremidchiev, and T. Velikova, How to use Safely COVID-19 Vaccines in Patients on Anticoagulants or Antiaggregants. International Journal of Preventive Cardiology, 2021. 1(1): p. 32-33.
The Lancet, H., COVID-19 vaccination in haematology services. Lancet Haematol, 2021. 8(2): p. e95.
Agrati, C., et al., Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient. Journal of cellular and molecular medicine, 2021: p. 10.1111/jcmm.16565.
Harrington, P., et al., Single dose of BNT162b2 mRNA vaccine against SARSCoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021: p. 1-5.
Herishanu, Y., et al., Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 2021. 137(23): p. 3165-3173.
Houot, R., et al., Could anti-CD20 therapy jeopardise the efficacy of a SARSCoV-2 vaccine? European Journal of Cancer, 2020. 136: p. 4-6.
Roeker, L.E., et al., COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia, 2021: p. 1-3.
Pimpinelli, F., et al., Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. Journal of Hematology & Oncology, 2021. 14(1): p. 1-12.
Hwang, J.K., et al., COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of hematology & oncology, 2021. 14(1): p. 1-11.
Giesen, N., et al., 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. European Journal of Cancer, 2021. 147: p. 154-160.
McCaughan, G., et al., COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021. 51(5): p. 763-768.
Tougeron, D., et al., Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). European Journal of Cancer, 2021. 150: p. 232-239.
ESC. COVID-19 vaccine information for heart patients. 2021 [cited 2021 2 July ]; Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/covid-19-and-vaccinations.
Driggin, E., et al., ACC health policy statement on cardiovascular disease considerations for COVID-19 vaccine prioritization: a report of the American college of cardiology solution set oversight committee. Journal of the American College of Cardiology, 2021. 77(15): p. 1938-1948.
AHA. COVID-19 vaccine is high priority for cardiac patients. 2021 [cited 2021 2 July ]; Available from: https://www.heart.org/en/beyond-thetable/stories/covid-19-vaccine-is-high-priority-for-cardiac-patients.
Verstraeten, T., et al., Diabetes mellitus as a vaccine-effect modifier: a review. Expert Review of Vaccines, 2020. 19(5): p. 445-453.
Pal, R., et al., Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021. 15(1): p. 193-196.
Dispinseri, S., et al., Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia. The Journal of Clinical Endocrinology & Metabolism, 2021. 106(5): p. 1472-1481.
Lampasona, V., et al., Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia, 2020. 63(12): p. 2548-2558.
Food and D. Administration, Emergency use authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Food and Drug Administration, Silver Spring, MS, USA, 2019.
Mahase, E., Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ: British Medical Journal (Online), 2020. 371.
Gee, J., First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR. Morbidity and mortality weekly report, 2021. 70.
(IDF), I.D.F. Diabetes & Coronavirus Vaccination. 2021 [cited 2021 10 June]; Available from: https://idf.org/our-network/regions-members/europe/europe-news/370-diabetes-coronavirus-vaccination.html.
Marjot, T., et al., SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol, 2021. 6(3): p. 156-158.
Bril, F., et al., Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol, 2021.
AASLD. COVID-19 AND THE LIVER. 2021 [cited 2021 12 June ]; Available from: https://www.aasld.org/about-aasld/covid-19-and-liver.
Fix, O.K., et al., AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease. Hepatology. n/a(n/a).
Alqahtani, S.A., et al., Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation. 2021.
Russo, F.P., et al., Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Dig Liver Dis, 2021. 53(6): p. 677-681.
Teijaro, J.R. and D.L. Farber, COVID-19 vaccines: modes of immune activation and future challenges. Nature Reviews Immunology, 2021: p. 1-3.
Heldman, M.R. and A.P. Limaye, SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know? Journal of the American Society of Nephrology, 2021. 32(5): p. 1021-1024.
Pormohammad, A., et al., Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel), 2021. 9(5).
Xing, K., et al., Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2021. 23(3): p. 221-228.
Yuan, P., et al., Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. medRxiv, 2020.
Kute, V., et al., NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian Journal of Transplantation, 2021. 15(1): p. 1.
Memberships, M. and T. Join, TID COVID-19 Guidance Focused Review: SARS-CoV-2 Vaccines in Transplant Recipients.
Yi, S.G., et al., Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation, 2021. 105(7): p. e72-e73.
Grupper, A., et al., Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. American Journal of Transplantation, 2021. 21(8): p. 2719-2726.
Benotmane, I., et al., Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int, 2021. 99(6): p. 1487-1489.
Benotmane, I., et al., Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int, 2021. 99(6): p. 1498-1500.
Nacif, L.S., et al., COVID-19 in solid organ transplantation patients: A systematic review. Clinics (Sao Paulo), 2020. 75: p. e1983.
Boyarsky, B.J., et al., Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. Jama, 2021.
Ali, N.M., et al., Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. Transplantation, 2021.
Curtis, J.R., et al., American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. Arthritis & Rheumatology, 2021. 73(8): p. e30-e45.
Marion, O., et al., Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine, 2021.
Connolly, C.M., et al., Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Annals of Internal Medicine, 2021.
Kathryn M Edwards, Walter A Orenstein, and A. Sacchi. COVID-19: Vaccines to prevent SARS-CoV-2 infection. 2021; Available from: https://www.uptodate.com/contents/covid-19-vaccines-to-prevent-sars-cov-2-infection.
Weinberger, B., et al., Biology of immune responses to vaccines in elderly persons. Clinical Infectious Diseases, 2008. 46(7): p. 1078-1084.
Jackson, L.A., et al., An mRNA vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine, 2020.
Anderson, E.J., et al., Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine, 2020. 383(25): p. 2427-2438.
Teo, S.P., Review of COVID-19 Vaccines and Their Evidence in Older Adults. Annals of geriatric medicine and research, 2021. 25(1): p. 4.
Torjesen, I., Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds. BMJ: British Medical Journal (Online), 2021. 373.
Lv, G., et al., Mortality Rate and Characteristics of Deaths Following COVID-19 Vaccination. Frontiers in Medicine, 2021. 8(649).
Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020. 383(27): p. 2603-2615.
FDA, F., Briefing Document, Moderna COVID-19 Vaccine. 2020, US Food and Drug Administration.
Werbel, W.A., et al., Safety and Immunogenicity of a Third Dose of SARSCoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med, 2021.
Shimabukuro, T.T., et al., Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine, 2021. 384(24): p. 2273-2282.
Atyeo, C., et al., COVID-19 mRNA vaccines drive differential Fcfunctional profiles in pregnant, lactating, and non-pregnant women. bioRxiv, 2021.
Beharier, O., et al., Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. The Journal of Clinical Investigation, 2021. 131(13).
Gray, K.J., et al., Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol, 2021.
Male, V., Are COVID-19 vaccines safe in pregnancy? Nature Reviews Immunology, 2021: p. 1-2.
Brillo, E., et al., COVID-19 vaccination in pregnancy and postpartum. J Matern Fetal Neonatal Med, 2021: p. 1-21.
Vincenzo Berghella and Brenna Hughes. COVID-19: Pregnancy issues and antenatal care. 2021 [cited 2021 6 June]; Available from: https://www.uptodate.com/contents/covid-19-pregnancy-issues-and-antenatal-care.
CDC-3. V-safe COVID-19 Vaccine Pregnancy Registry. 2021 2 June 2021 [cited 2021 6 June]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafepregnancyregistry.html.
Sajjadi, N.B., et al., United States internet searches for “infertility” following COVID-19 vaccine misinformation. Journal of osteopathic medicine, 2021.
Iacobucci, G., Covid-19: No evidence that vaccines can affect fertility, says new guidance. 2021, British Medical Journal Publishing Group.
Bowman, C.J., et al., Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol, 2021. 103: p. 28-35.
CDC-2, Updated healthcare infection prevention and control recommendations in response to COVID-19 vaccination. . 2021.
Goupil, R., et al., Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ, 2021. 193(22): p. E793-E800.
Boyarsky, B.J., et al., Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. Jama, 2021. 325(21): p. 2204-2206.
Monin, L., et al., Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology, 2021. 22(6): p. 765-778.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
